What is HC Wainwright’s Estimate for ZNTL Q1 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Wednesday, January 29th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.41) per share for the quarter, up from their prior estimate of ($0.65). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($2.03) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($1.42) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36.

Several other research firms have also weighed in on ZNTL. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. UBS Group cut their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Guggenheim dropped their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Stock Down 3.4 %

Shares of Zentalis Pharmaceuticals stock opened at $1.68 on Monday. The stock has a market cap of $119.72 million, a PE ratio of -0.67 and a beta of 1.82. The business has a fifty day simple moving average of $2.90 and a 200-day simple moving average of $3.24. Zentalis Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $18.07.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Verition Fund Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares during the period. Primecap Management Co. CA raised its holdings in shares of Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after purchasing an additional 265,690 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Zentalis Pharmaceuticals by 126.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after acquiring an additional 127,868 shares during the period. Finally, XTX Topco Ltd raised its holdings in Zentalis Pharmaceuticals by 8.7% in the 3rd quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after acquiring an additional 15,597 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.